Movatterモバイル変換

Indium (¹¹¹In) capromab pendetide

From Wikipedia, the free encyclopedia

Pharmaceutical compound

Indium (¹¹¹In) capromab pendetide
Monoclonal antibody
Type	Whole antibody
Source	Mouse
Target	Glutamate carboxypeptidase II
Clinical data
Trade names	Prostascint
ATC code	V09IB04 (WHO)
Identifiers
CAS Number	151763-64-3^N (capromab) 148805-91-8 (pendetide)
ChemSpider	none
UNII	03MZ53X1YS
ChEMBL	ChEMBL1201579^N
^NY (what is this?) (verify)

Indium (¹¹¹In) capromab pendetide (trade nameProstascint) is used to image the extent ofprostate cancer.^[1] Capromab is amouse monoclonal antibody which recognizes a protein found on both prostate cancer cells and normal prostate tissue. It is linked topendetide, a derivative ofDTPA.^[2] Pendetide acts as achelating agent for theradionuclide indium-111. Following an intravenous injection of Prostascint, imaging is performed usingsingle-photon emission computed tomography (SPECT).^[1]

Early trials with yttrium (⁹⁰Y) capromab pendetide were also conducted.^[3]

References

[edit]

^^a ^bManyak MJ (February 2008). "Indium-111 capromab pendetide in the management of recurrent prostate cancer".Expert Review of Anticancer Therapy.8 (2):175–81.doi:10.1586/14737140.8.2.175.PMID 18279057.S2CID 30587577.
^WHO Drug Information
^Kahn D, Austin JC, Maguire RT, Miller SJ, Gerstbrein J, Williams RD (April 1999). "A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy".Cancer Biotherapy & Radiopharmaceuticals.14 (2):99–111.doi:10.1089/cbr.1999.14.99.PMID 10850293.

Diagnosticradiopharmaceuticals (V09)

Central nervous system

Skeletal system

^99mTc (Medronic acid)

Renal

Gastrointestinal/Hepatic

⁷⁵Se (SeHCAT)

Respiratory system

Cardiovascular system

Inflammation/infection

Tumor

Adrenal cortex

Radionuclides
(includingtracers)

positron (PET list)

gamma ray/photon (SPECT/scintigraphy)

Isotopes used:

Monoclonal antibodies for tumors

Tumor

Human	Adecatumumab^§ Amivantamab Ascrinvacumab^§ Balstilimab^† Botensilimab Cixutumumab^§ Conatumumab^§ Cosibelimab Daratumumab Drozitumab^§ Duligotumab^§ Dusigitumab^§ Enfortumab vedotin Enoticumab^§ Figitumumab^§ Flanvotumab^§ Ganitumab^† Glembatumumab vedotin^† Intetumumab^§ Ipilimumab Iratumumab^§ Istiratumab Icrucumab^§ Lexatumumab^§ Linvoseltamab Lucatumumab^§ Mapatumumab^§ Narnatumab^§ Necitumumab Nesvacumab^§ Nivolumab^# (+hyaluronidase,+relatlimab) Ofatumumab Olaratumab^† Panitumumab Patritumab^§ Pritumumab^§ Radretumab^§ Ramucirumab Rilotumumab^† Robatumumab^§ Seribantumab^§ Sugemalimab Tarextumab^§ Tisotumab vedotin Teprotumumab^† Tovetumab^§ Vantictumab^§ Votumumab^§ Zalutumumab^†
Mouse	Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab^† Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Nofetumomab merpentan Pintumomab Tenatumomab Tositumomab
Chimeric	Amatuximab^§ Bavituximab^§ Brentuximab vedotin Carotuximab^† Cetuximab Derlotuximab biotin^§ Dinutuximab Ecromeximab^§ Ensituximab^§ Futuximab^§ Girentuximab^† Indatuximab ravtansine^§ Isatuximab Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab^# Siltuximab Ublituximab Zolbetuximab
Humanized	Abituzumab^§ Alemtuzumab Atezolizumab (+hyaluronidase) Axatilimab Belantamab mafodotin Bevacizumab Bivatuzumab mertansine^§ Brontictuzumab^§ Cantuzumab mertansine^§ Cantuzumab ravtansine^§ Cirmtuzumab Citatuzumab bogatox^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab^§ Demcizumab^§ Dalotuzumab^§ Datopotamab deruxtecan Denintuzumab mafodotin^§ Elotuzumab Emactuzumab Emibetuzumab^§ Enoblituzumab^§ Epcoritamab Etaracizumab^§ Farletuzumab^§ Ficlatuzumab^§ Flotetuzumab^§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab^§ Inotuzumab ozogamicin Labetuzumab^§ Lifastuzumab vedotin^§ Lintuzumab^§ Lorvotuzumab mertansine^§ Lumretuzumab^§ Matuzumab^§ Milatuzumab^§ Naxitamab Nimotuzumab^† Obinutuzumab Ocaratuzumab^§ Odronextamab Otlertuzumab^§ Onartuzumab^§ Oportuzumab monatox^† Parsatuzumab^§ Pembrolizumab^# (+berahyaluronidase alfa) Penpulimab Pertuzumab Pinatuzumab vedotin^§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine^† Sacituzumab govitecan Sibrotuzumab^§ Simtuzumab^§ Sofituzumab vedotin^§ Tacatuzumab tetraxetan^§ Tigatuzumab^§ Trastuzumab^# (+deruxtecan /+emtansine) Tucotuzumab celmoleukin^§ Vandortuzumab vedotin^§ Vanucizumab^§ Veltuzumab^§ Vorsetuzumab mafodotin^§ Zenocutuzumab
Rat/mouse hybrid	Catumaxomab Ertumaxomab^§
Chimeric + humanized	Depatuxizumab mafodotin^† Duvortuxizumab Ontuxizumab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Thismonoclonal antibody–related article is astub. You can help Wikipedia byexpanding it.

Thisantineoplastic orimmunomodulatory drug article is astub. You can help Wikipedia byexpanding it.

Thisnuclear medicine article is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Indium_(111In)_capromab_pendetide&oldid=1166038734"

Categories:

Hidden categories:

[8]ページ先頭